345 related articles for article (PubMed ID: 24334617)
21. Neurofibromin in neurofibromatosis type 1 - mutations in NF1gene as a cause of disease.
Abramowicz A; Gos M
Dev Period Med; 2014; 18(3):297-306. PubMed ID: 25182393
[TBL] [Abstract][Full Text] [Related]
22. SPRED1 mutations (Legius syndrome): another clinically useful genotype for dissecting the neurofibromatosis type 1 phenotype.
Spurlock G; Bennett E; Chuzhanova N; Thomas N; Jim HP; Side L; Davies S; Haan E; Kerr B; Huson SM; Upadhyaya M
J Med Genet; 2009 Jul; 46(7):431-7. PubMed ID: 19443465
[TBL] [Abstract][Full Text] [Related]
23. Epilepsy in Legius syndrome: Coincidence or causation?
Medina Lemus A; Boelman C; Myers KA
Am J Med Genet A; 2024 Jun; 194(6):e63547. PubMed ID: 38268057
[TBL] [Abstract][Full Text] [Related]
24. SPRED1 Interferes with K-ras but Not H-ras Membrane Anchorage and Signaling.
Siljamäki E; Abankwa D
Mol Cell Biol; 2016 Oct; 36(20):2612-25. PubMed ID: 27503857
[TBL] [Abstract][Full Text] [Related]
25. Identification of SPRED1 deletions using RT-PCR, multiplex ligation-dependent probe amplification and quantitative PCR.
Spencer E; Davis J; Mikhail F; Fu C; Vijzelaar R; Zackai EH; Feret H; Meyn MS; Shugar A; Bellus G; Kocsis K; Kivirikko S; Pöyhönen M; Messiaen L
Am J Med Genet A; 2011 Jun; 155A(6):1352-9. PubMed ID: 21548021
[TBL] [Abstract][Full Text] [Related]
26. Expanding the Noonan spectrum/RASopathy NGS panel: Benefits of adding NF1 and SPRED1.
Witkowski L; Dillon MW; Murphy E; S Lebo M; Mason-Suares H
Mol Genet Genomic Med; 2020 Apr; 8(4):e1180. PubMed ID: 32107864
[TBL] [Abstract][Full Text] [Related]
27. Legius syndrome: A case report.
Kimura R; Yoshida Y; Maruoka R; Kosaki K; Yamamoto O
J Dermatol; 2017 Apr; 44(4):459-460. PubMed ID: 28378438
[TBL] [Abstract][Full Text] [Related]
28. A novel NF1 mutation in a Chinese patient with giant café-au-lait macule in neurofibromatosis type 1 associated with a malignant peripheral nerve sheath tumor and bone abnormality.
Tong HX; Li M; Zhang Y; Zhu J; Lu WQ
Genet Mol Res; 2012 Aug; 11(3):2972-8. PubMed ID: 22869071
[TBL] [Abstract][Full Text] [Related]
29. SPRED proteins provide a NF-ty link to Ras suppression.
McClatchey AI; Cichowski K
Genes Dev; 2012 Jul; 26(14):1515-9. PubMed ID: 22802525
[TBL] [Abstract][Full Text] [Related]
30. Germline loss-of-function mutations in SPRED1 cause a neurofibromatosis 1-like phenotype.
Brems H; Chmara M; Sahbatou M; Denayer E; Taniguchi K; Kato R; Somers R; Messiaen L; De Schepper S; Fryns JP; Cools J; Marynen P; Thomas G; Yoshimura A; Legius E
Nat Genet; 2007 Sep; 39(9):1120-6. PubMed ID: 17704776
[TBL] [Abstract][Full Text] [Related]
31. Café-au-lait Macules and Neurofibromatosis Type 1: A Review of the Literature.
Bernier A; Larbrisseau A; Perreault S
Pediatr Neurol; 2016 Jul; 60():24-29.e1. PubMed ID: 27212418
[TBL] [Abstract][Full Text] [Related]
32. Pigment cell-related manifestations in neurofibromatosis type 1: an overview.
De Schepper S; Boucneau J; Lambert J; Messiaen L; Naeyaert JM
Pigment Cell Res; 2005 Feb; 18(1):13-24. PubMed ID: 15649148
[TBL] [Abstract][Full Text] [Related]
33. Updated Approach to Patients with Multiple Café au Lait Macules.
Albaghdadi M; Thibodeau ML; Lara-Corrales I
Dermatol Clin; 2022 Jan; 40(1):9-23. PubMed ID: 34799039
[TBL] [Abstract][Full Text] [Related]
34. Independent NF1 and PTPN11 mutations in a family with neurofibromatosis-Noonan syndrome.
Thiel C; Wilken M; Zenker M; Sticht H; Fahsold R; Gusek-Schneider GC; Rauch A
Am J Med Genet A; 2009 Jun; 149A(6):1263-7. PubMed ID: 19449407
[TBL] [Abstract][Full Text] [Related]
35. Atypical hematologic and renal manifestations in neurofibromatosis type I: coincidence or pathophysiological link?
Van-Gils J; Harambat J; Jubert C; Vidaud D; Llanas B; Perel Y; Lacombe D; Goizet C
Eur J Med Genet; 2014; 57(11-12):639-42. PubMed ID: 25234363
[TBL] [Abstract][Full Text] [Related]
36. Mutational spectrum by phenotype: panel-based NGS testing of patients with clinical suspicion of RASopathy and children with multiple café-au-lait macules.
Castellanos E; Rosas I; Negro A; Gel B; Alibés A; Baena N; Pineda M; Pi G; Pintos G; Salvador H; Lázaro C; Blanco I; Vilageliu L; Brems H; Grinberg D; Legius E; Serra E
Clin Genet; 2020 Feb; 97(2):264-275. PubMed ID: 31573083
[TBL] [Abstract][Full Text] [Related]
37. The neurofibromin recruitment factor Spred1 binds to the GAP related domain without affecting Ras inactivation.
Dunzendorfer-Matt T; Mercado EL; Maly K; McCormick F; Scheffzek K
Proc Natl Acad Sci U S A; 2016 Jul; 113(27):7497-502. PubMed ID: 27313208
[TBL] [Abstract][Full Text] [Related]
38. Impaired instrumental learning in Spred1
Borrie SC; Horner AE; Yoshimura A; Legius E; Kopanitsa MV; Brems H
Genes Brain Behav; 2021 Jun; 20(5):e12727. PubMed ID: 33624414
[TBL] [Abstract][Full Text] [Related]
39. Identification of a Novel
Xu G; Li M; Niu Y; Huang X; Li Y; Tang G; Long S; Zhao H; Jiang H
Biomed Res Int; 2019; 2019():2721357. PubMed ID: 31886188
[TBL] [Abstract][Full Text] [Related]
40. Legius syndrome in fourteen families.
Denayer E; Chmara M; Brems H; Kievit AM; van Bever Y; Van den Ouweland AM; Van Minkelen R; de Goede-Bolder A; Oostenbrink R; Lakeman P; Beert E; Ishizaki T; Mori T; Keymolen K; Van den Ende J; Mangold E; Peltonen S; Brice G; Rankin J; Van Spaendonck-Zwarts KY; Yoshimura A; Legius E
Hum Mutat; 2011 Jan; 32(1):E1985-98. PubMed ID: 21089071
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
